1	The bladder microbiome of chronic kidney disease
2	with associations to demographics, renal function, and serum cytokines
3	
4	Fengping Liu ^{1*} , Jingjie Du ^{2*} , Hao Lin ^{3*} , Zhenyi Xu ^{3*} , Yifan Sun ^{3*} , Feng Yan ^{4*} , Yifeng Gu ⁵ , Yang
5	Wang ³ , Wei Guo ³ , Qixiao Zhai ⁶ , Jialin Hu ³ , Yu Tian ³ , Lei Hu ³ , Peng Jiang ³ , Shichao Wei ³ ,
6	Chaoqun Gu ³ , Jiayi Sheng ³ , Wei Chen ⁶ , Alan J. Wolfe ² , Ninghan Feng ³
7	
8	¹ Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China
9	² Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University
10	Chicago, Maywood, Illinois, USA
11	³ Department of Urology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi,
12	Jiangsu, China
13	⁴ Department of Nephrology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi,
14	Jiangsu, China
15	⁵ Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key
16	Laboratory for Diagnosis and Treatment of Infectious Diseases, School of Medicine, The First
17	Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
18	⁶ State Key Laboratory of Food Science and Technology and School of Food Science and
19	Technology, Jiangnan University, Wuxi, Jiangsu, China
20	
21	[*] authors contributed equally to this article.
22	
23	Correspondences:
24	Wei Chen: qing_w2022@yeah.net. State Key Laboratory of Food Science and Technology and
25	School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu, China 214122
26	Alan J. Wolfe: awolfe@luc.edu. Department of Microbiology and Immunology, Stritch School of
27	Medicine, Loyola University Chicago, Maywood, Illinois, USA 60153
28	Ninghan Feng: n.feng@njmu.edu.cn. Department of Urology, Affiliated Wuxi No. 2 Hospital,
29	Nanjing Medical University, Wuxi, Jiangsu, China 21400

1

30 Abstract

31 Background

High throughput 16S rRNA gene sequencing and enhanced culture methods (e.g., expanded quantitative urine culture, EQUC) have established the existence of the human bladder microbiome. We aim to test the hypothesis that the bladder environment of patients with chronic kidney disease (CKD) differs from that of unaffected controls with associated consequences for the composition of the bladder microbiome.

37 Methods and Materials

Females (n=66) and males (n=66) diagnosed with CKD and age-BMI-matched healthy control (HC) females (n=22) and males (n=22) were recruited. Transurethral catheterized urine was collected for 16S rRNA gene sequencing and Expanded Quantitative Urine Culture (EQUC). Fecal samples also were sequenced. Urinary analysis, kidney function and serum cytokines were examined.

43 Results

44 Bladder microbiomes of CKD females and males versus HC females and males differed 45 (FDR<0.05); however, the difference was more obvious in females. In CKD females, sequencing 46 revealed depletion of 5 genera, including Lactobacillus, and enrichment of 14 genera, including 47 *Escherichia/Shigella*, *Bifidobacterium*, and several clostridial genera (FDR<0.05), while EQUC 48 detected increased Escherichia and decreased Lactobacillus CKDB(P<0.05). Escherichia-Shigella 49 was positively, whereas Lactobacillus was negatively, associated with CKDB-female serum 50 creatinine (r=0.285, P=0.020; r=-0.337, P=0.006, respectively). Lactobacillus was positively 51 associated with eGFR (r=0.251, P=0.042). Some CKD-related serum cytokines were negatively 52 associated with clostridial genera. In contrast, the fecal microbiomes of CKD and HC females and 53 males did not significantly differ in bacterial diversity or composition. However, bladder and fecal 54 microbiomes of CKD females resembled each other more than those of controls, as assessed by 55 the Bray-Curtis Dissimilarity Index (FDR<0.05).

56 Conclusions

57 CKD bladder microbiomes were dysbiotic, which was more obvious in females. This dysbiosis58 was associated with kidney damage severity and dysregulation of serum cytokines. The increased

- 59 similarity between bladder and fecal microbiomes of CKD females suggests possible
- 60 "gut-leakage."
- 61 Key words
- 62 bladder; chronic kidney disease; cytokine; fecal microbiome; kidney function; microbiome

63 1 Introduction

64 Chronic kidney disease (CKD) is a non-communicable disease that affects more than 10% of 65 the general population worldwide[1]. It is a progressive disease that over time leads to irreversible 66 nephron loss and kidney failure. However, CKD is uncured by current therapies, possibly due to 67 its unclear pathology. Previous studies found that microbial dysbiosis in human gut and blood is 68 associated with CKD[2, 3], and crosstalk between host and microbiome is pathophysiologically 69 relevant to CKD[2, 3].

70 The human bladder harbors its own microbial community[4-8]. Most studies have explored 71 associations between the microbiomes of urine samples obtained by transurethral catheter (bladder) 72 or midstream void (urogenital) and urinary tract disorders, such as urinary stone disease[9], 73 urinary tract infection (UTI)[10], and bladder cancer[11]. One study assessed the urogenital 74 microbiome in CKD patients and found it to be extremely diverse with greater diversity associated 75 with estimated glomerular filtration rate (eGFR). However, this study did not include controls and 76 analyzed voided urine samples[12], which often contains microbes from both the urinary and 77 genital tracts[13, 14].

Kidneys are a major site for elimination of many cytokines. The delicate equilibrium of proinflammatory cytokines and their inhibitors is dysregulated in CKD[15], and associated with gut dysbiosis in CKD[16, 17]. For example, the dysregulation of tumor necrosis factor (TNF- α) and interleukin-6 (IL-6) is associated with gut dysbiosis in CKD[16, 17].

With mounting evidence of an interaction between gut microbiome and kidney function, some researchers have proposed a gut-kidney axis[18, 19]. However, these researchers ignored the possible existence of microbiomes in the urinary tract[20, 21]. Given that microbes are exquisitely sensitive to their environments and are known to interact with their niches, we hypothesize that (1) CKD patients have a dysbiotic bladder microbiome, (2) the bladder microbiome distinguishes CKD patients better than the fecal microbiome, and (3) the bladder microbiome is associated with serum cytokines.

89 2 Materials and methods

90 2.1 Study participant recruitment

91 Participants were recruited from July 1st 2018 to March 30th 2020. **Figure S1** displays the study

92 design, including participant recruitment, methods, and objectives. Diagnostic criteria of CKD 93 included decreased eGFR [<60 mL/min/1.73m² or evidence of kidney damage, such as 94 albuminuria (albumin excretion rate \geq 30 mg/24 h; urinary albumin creatinine ratio [UACR] \geq 30 95 mg/g], urine sediment abnormalities, electrolyte and other abnormalities due to tubular disorders, 96 abnormalities detected by histology, and/or structural abnormalities detected by imaging or history 97 of kidney transplantation[22]. CKD patients undergoing hemodialysis were excluded. 98 Asymptomatic controls ("healthy" controls, HC) were recruited if they had an eGFR≥90 99 ml/min/1.73m² and were free of current renal damage, a history of liver disease, cancer, diabetes, 100 hypertension, and hyperlipidemia. After recruitment, HC subjects were excluded if they had an 101 indicator of urinary tract infection (UTI) by urinalysis, such as >5 WBCs/HPF, >3 RBCs/HPF, 102 positive urine nitrites, positive leucocyte esterase, positive occult, positive protein, and abnormal 103 values of diabetes, hypertension, hyperlipidemia. Any participant with acute intercurrent disease 104 or infection, diarrhea, kidney transplantation, pregnancy, breastfeeding was excluded. Those who 105 used antibiotics, probiotics or immunosuppressive drugs within 30 days before enrollment also 106 were excluded.

107 2.2 Urine collection and storage

108 Bladder urine samples were collected by transurethral catheterization and stored as reported 109 previously[23]. Before catheter insertion, 5% iodophor was applied to disinfect the genital and 110 perineal areas. Fifty mL urine were obtained and separated into three portions (i.e., 30 mL, 5 mL 111 and 15 mL) that were used for 16S rRNA gene sequencing, Expanded Quantitative Urine Culture 112 (EQUC) and clinical urinary analysis^[4], respectively. All samples were processed in a biosafety 113 cabinet. Samples for 16S rRNA gene sequencing and EQUC were placed in sterile, DNA- and 114 enzyme-free centrifuge tubes. Samples for 16S rRNA gene sequencing were stored at -80°C 115 refrigerator within 15 mins after collection. Samples for EQUC were placed in an insulated sterile 116 container, immediately cooled on ice, and transferred to the research personnel within 4 hours.

117 2.3 Expanded Quantitative Bladder Urine Culture

Methods for EQUC were modified according to previous studies[6, 24]. 0.1 mL of catheterized
bladder urine was inoculated onto BAP, chocolate and colistin, as well as nalidixic acid agars
(Kemajia inc., Shanghai, China), streaked for quantification, and incubated in 5% CO₂ at 35°C for

121 48h. Next, 0.1 mL of urine was inoculated onto two CDC anaerobe 5% sheep blood agar plates 122 and incubated in an anaerobic incubator with a Campy gas mixture (5% O₂, 10% CO₂, 85% N₂) at 123 35°C for 5 days. 1.0 mL of urine was placed in thioglycolate medium and incubated aerobically at 124 35° C for 5 days. If growth was visually detected in the thioglycolate medium, the medium was 125 mixed, and 0.01 mL of urine was plated on BAP and CDC anaerobe 5% sheep blood agars for 126 isolation and incubated aerobically and anaerobically at 35°C for 48h. Each morphologically 127 distinct colony type was isolated on a different plate of the same media to prepare a pure culture 128 that was used for identification, as described below.

129 2.4 16S rRNA gene sequencing

130 Bacterial DNA isolation from urine was described previously [6, 24]. The quantity and quality 131 of the extracted DNA was measured using a NanoDrop ND-1000 spectrophotometer (Thermo 132 Fisher Scientific, Waltham, MA, USA) and agarose gel electrophoresis. Using the isolated DNA as 133 the template, the bacterial 16S rRNA V3-V4 region was PCR-amplified for 32 cycles using 134 universal primers 338F and 806R. The resultant PCR amplicons were purified with Agencourt 135 AMPure XP Beads (Beckman Coulter, Indianapolis, IN, USA) and quantified using the PicoGreen 136 dsDNA Assay Kit (Invitrogen, Carlsbad, CA, USA). Amplicon pools were prepared for 137 sequencing, and the size and quantity of the amplicon library were assessed using an Agilent 2100 138 Bioanalyzer (Agilent, Santa Clara, MA, USA) and Library Quantification Kit for Illumina (Kapa 139 Biosciences, Woburn, MA, USA), respectively. The libraries were sequenced using the NovaSeq 140 6000 platform. As urines are low-biomass samples, they were sequenced in duplicate for 141 reproducibility. When the Bray-Curtis dissimilarity of the duplicated urinary microbiome samples 142 was above 0.3[25], they were re-sequenced. If their Bray-Curtis dissimilarity remained above 143 0.3[25], they were removed from further analysis. Six negative controls (2 without urine, 2 144 without bacterial DNA, and 2 without PCR product) also were sequenced.

145 2.5 Bioinformatic analysis of 16S rRNA gene sequencing data

Raw reads of the 16S rRNA gene sequences were trimmed using Cutadapt (cutadapt.readthedocs.io) to remove barcodes and adaptors. The overlapping paired-end reads were merged into a longer tag using FLASH (v1.2.8). Reads were quality trimmed using fdtrim (v0.94) from the 3' end to remove bases with low-quality scores. Reads shorter than 100bp, with

more than 5% Ns, or with an average quality below 20 were discarded. Chimeras were removed using Vsearch (v2.3.4). QIIME2 was used to process the clean reads to generate an ASV table, and taxonomy of microbes was identified using the Silva database (v138). Environmental contaminants of urine samples were removed as previously described[20]. Bacterial ASVs whose counts did not exceed five times the maximum number of counts in the negative controls were considered as contaminates and removed, as described[20]. We also manually removed bacteria that have been reported to be environmental contaminants from soil and water.

157 2.6 Identification of bacterial isolates

158 2.6.1 16S rRNA gene sequencing of bacterial isolates

159 Bacterial isolates purified as described above were harvested: if the colonies were large enough, 160 a single colony was chosen; if not, then the plate was scraped. To the harvested bacteria, 200μ L 161 lysis buffer (Guhe, Hangzhou, China) was added and its DNA extracted using the method 162 described above for 16S rRNA gene sequencing. Identification of the isolates was confirmed by 163 partial sequencing of the 16S rRNA gene. Briefly, the 16S rRNA gene was amplified for 30 cycles 164 by PCR with universal primers 27F and 1492R, which results in an amplicon of approximately 165 1500 bp. PCR was performed in a DNA thermocycler (Thermo Scientific, USA) with PCR Premix 166 (Ensure biologicals, Shanghai, China) in 50 µL reaction mixtures. The resultant amplicons were sequenced with the ABI PrismTM BigdyeTM terminator cycle sequencing reaction kit (Applied 167 168 Biosystems, USA) using the 27F and 1492R primer pair. The sequencing product was purified 169 using the Millipore-Montage dye removal kit (Ensure Biologicals, Shanghai, China) and 170 sequenced on an ABI 3730XL capillary DNA sequencer (Applied Biosystems, USA). For each run, 171 negative controls containing water instead of template DNA were run in parallel. All sequencing 172 procedures were performed by BGI (Shanghai, China). For taxonomic identification, a portion of 173 the sequence compared to sequences in GenBank public database was 174 (http://www.ncbi.nlm.nih.gov/BLAST/).

175 2.6.2 MALDI-TOF MS identification of bacterial isolates

When a bacterial isolate could not be identified by 16S rRNA gene sequencing, we used
Matrix-Assisted Laser Desorption Ionization-Time-Of-Flight Mass Spectrometry (MALDI-TOF
MS), as described previously[4]. Briefly, a small portion of a single colony was overlaid with 1 µL

179 of a saturated solution of alpha-cyano-4-hydroxycinnamic acid matrix in 50% acetonitrile and 2.5% 180 trifluoroacetic acid (VITEK MSCHCA, bioMérieux), then air dried. Escherichia coli (ATCC 8739) 181 was used for system calibration. Mass spectra were acquired using a VITEK MS Plus (bioMérieux, 182 Marcy l'Etoile) and the bioMérieux VITEK MS (IVD Knowledgebase v.3.2) used to analyze a 183 composite mass spectrum for accurate identification. A probability score between 60% and 99.9% 184 was considered to be a high discrimination value and thus a reliable identification. A probability 185 score <60% was considered to be a low discrimination identification. No identification resulted 186 when either no match was found for the composite spectra, or the analysis did not obtain enough 187 spectral peaks [26]. Isolates that yielded no identification results were redeposited on the target 188 plate and reanalyzed.

189 2.7 Other sample collection and processing

190 Blood samples for assessment of renal function and serum cytokines were collected on the day of urinary sample collection. The Bio-PlexTM 200 System (Bio-Rad) and Bio-Plex ProTM Human 191 192 Cytokine Screening 48-plex Panel (Bio-Rad, California, USA) were used to detect serum 193 cytokines. An aliquot of bladder urine (described above) was used for urinalysis. The 24-hour 194 urine volume was collected one day prior to the day of bladder microbiome sample collection. 195 Fecal samples were collected on the day of bladder urine sample collection. The participants were 196 told to excrete their feces into a sterile container. A nurse then put 30 mg feces into a sterile tube 197 using sterile technique and stored them at -80°C refrigerator within 15 mins of collection. DNA 198 isolation and sequencing of fecal samples was the same as for the urine samples, except that they 199 were sequenced only once, as we have found that Bray-Curtis values for feces samples are 200 typically <0.3.

201 2.8 Disease profiles assessment

202 Participants' demographics data were collected during a face-to-face interview. Blood pressure203 and fasting blood glucose were assessed on the day of urine and fecal sample collection.

204 2.9 Statistical analysis

Pearson's Chi-square or Fisher's exact tests were used with categorical variables; Student's *t* test was used on normalized continuous variables and Wilcoxon rank-sum test was used on non-normal continuous variables. The *P*-value was adjusted for multiple comparisons using the

- 208 Benjamini–Hochberg (BH) false discovery rate (FDR). The significance threshold was set at an
- 209 FDR-corrected value <0.05. Pearson correlation analysis was used to assess associations between
- 210 variables, and the significance threshold was set at a P value <0.05.
- 211 3 Results
- 212 3.1 Participants

213 Figure **S1** displays the process, including participant recruitment, methods, and study objectives. 214 Briefly, we collected urine samples through sterilized catheter from 230 CKD patients and 176 215 controls. All participants with catheterized urine (i.e., bladder) samples with bacterial DNA below 216 the level of detection and control participants with abnormal urinalysis values were removed from 217 downstream analysis. To ensure reproducibility, bladder urine samples were sequenced in 218 duplicate, and participants whose samples were dissimilar (i.e., had a Bray-Curtis Dissimilarity 219 score above 0.3) were removed from downstream analysis. From the remaining participants, 220 age/BMI-matched CKD and HC males and females, resulting in 66 bladder urine samples from 221 CKD males (CKDB-male) and 22 bladder samples from HC males (HCB-male) and 66 bladder 222 samples from CKD females (CKDB-female) and 22 urine samples from HC females 223 (HCB-female).

224 Compared to the HCB groups, both the male and female CKDB groups had higher rates of 225 hypertension and diabetes, as well as higher rates of occult blood and cast in their urine (Fisher's 226 exact test, P<0.05; **Table 1**). Although both male and female CKDB groups had higher levels of 227 systolic blood pressure than those in controls, only female patients had a higher level of diastolic 228 blood pressure than that in controls (t-test, P<0.05; Table 1). Compared to HCB-males and 229 HCB-females, the CKDB-males and CKDB-females had lower levels of eGFR and higher levels 230 of serum creatinine, whereas the CKDB-males had a higher level of blood urea nitrogen and 231 CKDB-females had a higher level of uric acid (*t*-test, P<0.05; **Table 1**). No difference was found 232 in the nutrient intake between the groups of CKD and HC (*t*-test, P<0.05, **Table S1**); thus, it was 233 not considered to be a confounding factor in downstream analyses.

234 3.2 Bladder microbiomes are altered in CKD males and females

As gender difference has been reported to impact the bladder microbiome in asymptomatic subjects and disease groups[27, 28], we wondered whether the bladder microbiome composition

of females and males differed between our CKDB and HCB groups. To test this, we performed principal-coordinate analysis (PCoA) of Bray-Curtis Dissimilarity indices for all microbial taxa (ASVs) present within and among the microbiomes of each group. As expected, the bladder microbiome of HCB-males and HCB-females was significantly separated (R^2 =0.077, FDR=0.002; **Figure 1A**); the bladder microbiome of CKDB-males and CKDB-females was also separated but less so (R^2 =0.017, FDR=0.016; **Figure 1A**). Since the bladder microbiome of males and females differed, further analyses were performed separately.

244 When comparing CKDB to HCB, we found that the bladder microbiomes of both males and 245 females differed (PERMANOVA, R²=0.033, FDR=0.001 and R²=0.072, FDR<0.001, respectively; 246 Figure 1A). Hypertension, glucocorticoid levels, hypoglycemia and hypolipidemic agents were 247 not confounding factors, as bladder microbiome of the medication users and gender-age matched 248 non-users did not differ (PERMANOVA, FDR>0.05; Figure S2A-D). The bladder microbiome of 249 CKDB-males and CKDB-females was significantly more diverse than those of their respective 250 HCB controls. For females, this was reflected in both the number ASVs (Figure 1B) and the Chao 251 1 index, which estimate bacterial richness (Wilcoxon rank-sum test, FDR<0.001; Figure 1C); for 252 males, this increased richness was reflected only in the number of ASVs (Figure 1B). To assess 253 whether bacterial richness was associated with renal function in CKDB females, we performed a 254 Pearson correlation analysis between Chao1 and estimators of renal function (i.e., eGFR, serum 255 creatinine, blood urea nitrogen, and serum uric acid), but no association was observed (P>0.05).

256 3.3 Bladder microbiome composition is altered in CKD patients

257 Proteobacteria, Firmicutes, Actinobacteriota, Bacteroidota and Fusobacteriota were the 5 most 258 abundant phyla in the bladder microbiomes of all 4 groups (Figure 1D). After correction for 259 multiple testing, we observed no significant difference when we compared CKDB-males and 260 HCB-males, and CKDB-females and HCB-females (Wilcoxon rank-sum test, FDR>0.05; Table 261 S2 & S3). Notably, at the genus level, both the CKDB-males and CKDB-females were enriched 262 for Escherichia-Shigella (9.59% and 17.71%, respectively), and Enterococcus (3.34% and 5.63% 263 respectively; Figure 1E). Next, we compared bacterial genera that accounted for >0.1% of the 264 total relative abundance in males and females. After correction for multiple testing, we observed 265 no significant difference when we compared CKDB-males and HCB-males (Wilcoxon rank-sum

266 test, FDR>0.05; Table S4). In contrast, 19 genera differed significantly between CKDB-females 267 and HCB-females (Wilcoxon rank-sum test, FDR<0.05; Table S5). Five genera were significantly 268 less abundant in CKDB-females relative to HCB-females (Wilcoxon rank-sum test, FDR<0.05). 269 These included one unknown genus in the family Comamonadaceae and the genera Lactobacillus, 270 Sphingobium, Sphingomonas, and Streptomyces (Table S5; Figure 2A). Fourteen genera were 271 significantly more abundant in CKDB-females, including *Escherichia-Shigella*. Others included 272 Agathobacter, Anoxybacillus, Bacteroides, Bifidobacterium, Blautia. Comamonas. 273 Diaphorobacter, [Eubacterium] coprostanoligenes group, Faecalibacterium, CAG-352 in the 274 family Ruminococcaceae, Sphingobacterium, and Subdoligranulum (Wilcoxon rank-sum test, 275 FDR<0.05; Table S5; Figure 2B). Many of these taxa are members of the class Clostridia. As 276 Escherichia-Shigella is one of most common causes of UTI[29, 30], and the participants with 277 current UTI were excluded, we compared the abundance of *Escherichia-Shigella* between the 278 age-matched CKDB-female urine samples with positive urinary leucocyte esterase and negative 279 ones but there was no significant difference between the positive samples and negative ones 280 (29.82±45.23 vs. 24.73±39.24 (Wilcoxon rank-sum test, P=0.781, FDR=0.814). In addition, since 281 Lactobacillus can impede Escherichia growth in the urinary tract[31], we performed Pearson 282 correlation analysis to examine whether they were connected but there was no significant 283 correlation (r=-0.221, P=0.075).

284 To determine whether the detected sequences came from live bacteria, we performed EQUC 285 (**Table S6**), an enhanced culture method that vastly outperforms the standard clinical microbiology 286 urine culture method [4, 32]. Microbes (including both bacteria and fungi) were more prevalent in 287 HCB-females than in HCB-males (68.2 vs 13.6%, P<0.001; Table S7), whereas microbes were 288 only slightly more prevalent in CKDB-females than in CKDB-males (51.1 vs 42.4%, P=0.295; 289 **Table S8**). Microbes also were more prevalent in CKDB-males than in HCB-males (42.2 vs. 290 13.6%, P=0.014; Table S9). In contrast, microbes were equally prevalent in CKDB-females and 291 HCB-females (51.5 vs 68.2%, P=0.173; Table S10).

Only two identified genera and one unidentified genus were detected in HCB-males: the fungus *Cladosporium* was detected in one (4.5%), the bacterium *Curtobacterium* was detected in another
(4.5%), and an unidentified genus was detected in a third (4.5%). In contrast, multiple genera were

detected in CKDB-males. The most prevalent genera were *Bacillus* [18.18% (11/66)], *Staphylococcus* [9.09% (6/66)], *Kocuria* [3.03% (2/66)], *Micrococcus* [3.03% (2/66)], and *Paenibacillus* [3.03% (2/66)]. The genus *Bacillus* was significantly more prevalent in the
CKDB-males relative to HCB-males (Fisher's exact test, P=0.031; Figure 3A).

Although the overall prevalence of microbes did not differ between HCB-females and CKDB-females, many genera differed (**Figure 3B**). The most prevalent in HCB-females were *Bacillus* [22.73% (5/22)], *Lactobacillus* [22.73% (5/22)], and *Herbaspirillum* [13.64% (3/22)],

302 whereas the most prevalent in CKDB-females were *Bacillus* [15.15% (10/66)], *Escherichia* [7.58%

303 (5/66)], and Rothia spp. [4.55% (3/66)]. The genera Lactobacillus and Herbaspirillum were

304 significantly less prevalent in CKDB-females than in HCB-females (Fisher's exact test, P<0.05;

305 Figure 3B).

306 3.4 Altered genera in CKD was associated with demographics and renal function

307 Because the bladder microbiome composition of CKDB-females and HCB-females differed, we 308 used Pearson correlation analysis to determine whether any of the significantly different taxa (as 309 determined by 16S rRNA gene sequencing) were associated with any demographic category or 310 renal function. For CKDB-females, multiple associations were observed (Figure 4A). For 311 example, Escherichia-Shigella was positively associated with CKDB-female serum creatinine 312 (r=0.285, P=0.020). Lactobacillus was negatively associated with CKDB-female age and serum 313 creatinine (r=-0.330, P=0.007 and r=-0.337, P=0.006; respectively), but positively associated with 314 CKDB-female eGFR (r=0.251, P=0.042). Bifidobacterium was positively associated with 315 CKDB-female disease duration (r=0.335, P=0.006). In contrast, significant associations were not 316 observed for HCB-females (r<0.03, P>0.05; Figure 4B), with one exception: Streptomyces was 317 positively associated with blood urea nitrogen (r=0.790, P<0.001).

318 3.5 Bacterial community altered in all stages of CKD patients

For each CKD stage, we performed PCoA of Bray-Curtis Dissimilarity indices, comparing their bladder microbiomes to gender- and age-matched controls; these microbiomes differed significantly in stages 2-5 (PERMANOVA, FDR<0.05), but not stage 1 (PERMANOVA, FDR>0.05; **Figure S3A**). These differences were primarily due to changes in composition, as only CKDB microbiomes from stages 3 and 5 were significantly richer than their respective HCB (as

324 measured by Chao 1; Wilcoxon rank-sum test, FDR<0.05) and the Shannon indices did not differ

325 (Figure S3B).

326 **3.6** Altered bladder microbiome associated with altered serum cytokines in CKD patients

327 To determine if associations exist between the bladder microbiome and serum cytokines, we 328 first measured serum cytokines and then compared them to the bladder microbiome. Of the 48 329 serum cytokines we assessed, 44 cytokines were detected. Of these, 23 cytokines differed 330 significantly between the 66 CKD females and 22 female controls (Wilcoxon rank-sum test, 331 FDR<0.001). Some, such as IL-8, IL-18, IL-1 β and TNF- α were increased in CKD females, 332 whereas others, such as IL-9 and TNF- β were decreased in CKD females (Figure 5A). To 333 determine whether associations existed between serum cytokines and bladder microbial 334 composition, we performed Pearson correlation analysis. Several taxa enriched in HCB-females 335 were negatively associated with increased serum cytokines (r>0.03, P<0.05; Figure 5B). For 336 example, the genera Sphingobium and Streptomyces were negatively associated with IL-18, IL-8, 337 and/or IL-1^β. In contrast, several taxa enriched in CKDB-females were positively associated with 338 increased levels of serum cytokines (r>0.03, P<0.05; Figure 5B). For example, *Bifidobacterium* 339 was positively associated with IL-2R α , and MIG (r>0.03, P<0.05), and IL-8 was positively 340 associated with the members of Clostridia, including Agathobacter, Blautia, Faecalibacterium, 341 Subdoligranulum (r>0.03, P<0.05). Intriguingly, the genus Lactobacillus was enriched in 342 HCB-females but none of the correlations were statistically significant (Figure 5B).

343 3.7 Alteration of microbiome not observed in feces

344 To assess the gut-bladder axis in CKD, we assessed the fecal and bladder microbiomes of 345 CKD-males (n=10) to age-matched HC-males (n=10) and CKD-females (n=22) with age-matched 346 HC-females (n=22) who provided both fecal and catheterized urine samples. We observed no 347 difference in gut microbiome compositions (PERMANOVA, FDR>0.05; Figure 6A) or alpha 348 diversity (Wilcoxon rank-sum test, FDR>0.05; Figure 6B) between fecal samples from CKD 349 males (CKDF-males) and fecal samples from HC males (HCF-males) or between fecal samples 350 from CKD females (CKDF-females) and fecal samples from HC females (HCF-females). To test 351 the hypothesis that gut-kidney leakage occurs in CKD patients, we first performed PCoA on the 352 bladder and fecal microbiomes in CKD patients and controls; the bladder microbiomes differed

353 significantly from the corresponding fecal microbiomes for both CKD-males and females and 354 their age-matched HC-controls (PERMANOVA, FDR<0.05; Figures 6C-6F). We then compared 355 the Bray-Curtis dissimilarity between the bladder and gut microbiomes from either CKD 356 males/females or HC males/females. These microbiomes tended to be less dissimilar in 357 CKD-females than in HC-females (Wilcoxon rank-sum test, FDR<0.001), but not in the males 358 (Wilcoxon rank-sum test, FDR>0.05; Figure 6G). In addition, the Bray-Curtis dissimilarity 359 between the bladder and gut microbiomes from CKD females was slightly less than that from 360 CKD males (0.965±0.068 vs. 0.983±0.048, Wilcoxon rank-sum test, FDR=0.089), while the 361 Bray-Curtis dissimilarity between the bladder and fecal microbiomes from healthy females was 362 almost equal to that from healthy males (0.998±0.005 vs. 0.998±0.004, Wilcoxon rank-sum test, 363 FDR=0.472).

364 Discussion

The role of a balanced intestinal microbiome in maintaining kidney function is widely recognized[2]; however, the role of the bladder microbiome in kidney functions remains understudied. This study is the first to reveal that CKD patients possess a distinct bladder microbiome, and that the bladder microbial profile is associated with unbalanced kidney function and dysregulated serum cytokine profiles.

First, we found that both male and female CKD patients had dysbiotic bladder microbiomes, as assessed by 16S rRNA gene sequencing. This dysbiosis may be associated with loss of kidney function, as the bladder microbiomes of CKD patients in stages 2-5 differed from those of controls. A similar phenomenon in the gut was described by Wu et al., who reported that the fecal microbiome could reflect the CKD stage[33].

We observed an increased microbial richness in CKD patients relative to controls and found that this increase was greater in females than in males, as assessed by both sequencing and EQUC. Since population-based studies show that CKD affects more females than males[34], bladder dysbiosis in the context of CKD sex differences is worthy of future exploration.

One striking finding of this study is that CKD females' bladder microbiome was enriched for the genus *Escherichia/Shigella*, as assessed by both 16S rRNA gene sequencing and EQUC. This genus was not associated with urinary leucocyte esterase or serum cytokine profile, but its

increase in CKD females was positively correlated to the level of serum creatinine, a kidney function estimator. Given that *Escherichia/Shigella* is the most commonly detected genus in UTI[29, 30], its increased prevalence at relatively high abundance in CKD females indicate that this potentially uropathogenic microbe should be a concern during treatment of CKD.

386 Another notable finding of this study is that both detection methods (sequencing and EQUC) 387 revealed a depletion of *Lactobacillus* in CKD females. Decreased *Lactobacillus* has been reported 388 in patients with UTI[35], and may be a sign of an unhealthy bladder. Even though we did not 389 observe an association between *Lactobacillus* and serum cytokines like previous urinary 390 microbiome studies on interstitial cystitis and systemic lupus erythematosus suggested [20, 36], 391 Lactobacillus was associated with the kidney function indicators. It was positively associated with 392 eGFR and negatively associated with serum creatinine, indicating that *Lactobacillus* in the bladder 393 may be a biomarker for kidney function. Although the effects of bladder *Lactobacillus* on kidney 394 functions have never been reported, *Lactobacillus* oral supplementation in mouse models has been 395 suggested to attenuate the loss of kidney function, in a process that involved inflammation 396 pathways[37, 38]. Thus, *Lactobacillus* in the bladder might protect kidney function in females.

397 While decreased *Lactobacillus* in the vagina is a well-documented feature of older females, 398 recent studies have shown this decrease to also be true of the bladder. Komesu et al. found that the 399 relative abundance of *Lactobacillus* in catheterized urine had a strong negative relationship with 400 age when study participants with mixed urinary incontinence and controls were assessed 401 together[39]. Another study demonstrated that Lactobacillus in mid-stream voided urine was more 402 common in pre-menopausal females comparing to post-menopausal ones[40]. In contrast, our 403 study found a negative association between bladder Lactobacillus and age only in female CKD 404 patients. This finding suggests that loss of kidney function, a sign of getting older[41], may be 405 attributable to Lactobacillus depletion.

Bifidobacterium is widely advocated as a probiotic due to its potential beneficial effects[42]. However, in our study, bladder *Bifidobacterium* was enriched in CKD females and positively associated with disease duration and MIG, a chemoattractant cytokine for activated T lymphocytes and tumor infiltrating T-lymphocytes[43], and an indication of an unhealthy kidney, e.g. kidney cancer or stones[44, 45]. Increased *Bifidobacterium* also has been reported in patients with kidney

411 stones[21]. *Bifidobacterium* has been reported in bladder infections and other diseases [46-48].

412 Therefore, it is unclear whether *Bifidobacterium* in the bladder serves as a probiotic or not.

413 The upregulation of IL-1 β , IL-8, IL-18 and TNF- α in CKD patients have been reported[49-51]. 414 As expected, all these cytokines were upregulated in the serum of CKD females, and almost all 415 were negatively associated with decreased Sphingobium in CKD female bladders. As Sphingobium 416 has been rarely reported, the roles of these associations remain to be examined in the future. It is 417 worth noting that half of the bacterial genera enriched in CKD females are members of the class 418 Clostridia, including Agathobacter, Blautia, Faecalibacterium and Subdoligranulum, and all were 419 positively linked to the increase of the level of IL-18 in patients. Some members of Clostridia, 420 including Clostridiales, Lachnospiraceae and Ruminococcaceae, have been reported to be enriched 421 in the voided urine of patients with chronic prostatitis[52]. It is reasonable to conclude that 422 Clostridia plays a pathogenic role in CKD females.

To explore the gut-kidney axis, we assessed the fecal and bladder microbiomes in age-gender-matched CKD patients and controls. We only observed a statistical difference in the bladder microbiome. Using the Bray-Curtis Dissimilarity Index, we compared the fecal and bladder microbiomes and observed a statistically significant decrease in the female CKD patients but not in the matched controls, supporting the hypothesis that "gut-leakage" may occur in CKD females.

429 Our study has limitations. First, the number of CKD patients and age-gender-BMI matched 430 controls were unequal with a 3:1 patient:control ratio. Thus, there may exist additional 431 confounders that vary within the patients and controls[53]. However, kidney-age-related problems 432 are one of the most common health issues in elderly population[41], so it was difficult to recruit 433 healthy matched controls. Second, we only enrolled from a single institution which cannot 434 appropriately power the genetic profiles[54].

In summary, our study shows that the bladder microbiome of patients with CKD differs significantly from that of the controls, especially in females. The bladder microbiomes of CKD patients are richer (i.e., include more taxa) and many of those taxa are distinctly different in prevalence and abundance between two groups. Both 16S rRNA gene sequencing and EQUC detected a significant increase of *Escherichia/Shigella* and a significant decline of *Lactobacillus* in

440	CKD females, and such alterations may be related to reduced kidney function. We observed
441	associations between several bacterial genera in the bladders of CKD patients with several
442	CKD-associated serum cytokines, suggesting that these genera might play a pathological role.
443	Lastly, bladder dysbiosis was accompanied by "gut-leakage" in CKD females. Further studies are
444	needed to investigate how the bladder microbiome modifies kidney function, inflammation and
445	"gut leakage" using CKD animal models.

446 **Declarations**

447 Ethics approval and Consent to participate

- 448 The ethics committee of the Affiliated Wuxi Second Hospital of Nanjing Medical University
- 449 approved the study (Ref. 2018051). Informed consent was provided by all subjects prior to sample
- 450 collection.

451 Consent for publication

452 All authors consent to the publication of this manuscript.

453 Availability of data and materials

- 454 Raw data from 16S rRNA sequencing are available in the Sequence Read Archive under
- 455 BioProject ID SRP360378 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA807874).

456 Competing interests

- 457 All authors declare that they have no competing interests.
- 458 Funding
- 459 Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project
 460 (THRCJH20200901); Wuxi "key medical discipline construction" Municipal Clinical Medical
- 461 Center (municipal public health center) Project (LCYXZX202103); Wuxi Technological Project
- 462 (N20192047); Zhejiang Provincial Natural Science Foundation of China (LXR22H160001);
- 463 National Natural Science Foundation of China (81874142 and 82073041).
- 464 Authors' contributions
- 465 Conceptualization: Fengping Liu, Alan J. Wolfe, Wei Chen, and Ninghan Feng; methodology:
- 466 Fengping Liu, Jingjie Du, Qixiao Zhai, Hao Lin, Yifan Xu, Feng Yan, Yang Wang, Wei Guo,
- 467 Zhenyi Xu, Jialin Hu, Peng Jiang, Chaoqun Gu, Jiayi Sheng, Lei Hu; software: Fengping Liu, and
- 468 Jingjie Du; validation: Alan J. Wolfe; writing: Alan J. Wolfe, Fengping Liu, Jingjie Du, Yifeng
- 469 Gu; supervision: Alan J. Wolfe; funding acquisition: Ninghan Feng; project administration:
- 470 Fengping Liu, Jialin Hu, Lei Hu, Peng Jiang, Jiayi Sheng, Chaoqu Gu, Yang Wan, FengYan, Hao
- 471 Lin, Shichao Wei.

472 Acknowledgements

- 473 We gratefully acknowledge the volunteers who participated in our study.
- 474 Authors' information

- 475 ¹ Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China
- 476 ² Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University
- 477 Chicago, Maywood, Illinois, USA
- 478 ³ Department of Urology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi,
- 479 Jiangsu, China
- 480 ⁴ Department of Nephrology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi,
- 481 Jiangsu, China
- 482 ⁵Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key
- 483 Laboratory for Diagnosis and Treatment of Infectious Diseases, School of Medicine, The First
- 484 Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
- 485 ⁶ State Key Laboratory of Food Science and Technology and School of Food Science and
- 486 Technology, Jiangnan University, Wuxi, Jiangsu, China

487

488 Legends

- 489 Table 1 Demographics of urine donors of CKD patients and controls
- 490 Pearson Chi-square or Fisher's exact test was used with categorical variables; Student's t test on normalized
- 491 continuous variables was used.
- 492

493 Figure 1 Bacterial composition, Venn, bacterial diversity, and phylum and genus composition in the urine from 494 CKD patients and HC. (A) PCoA based on Bray-Curtis distances ASV level showed different microbial 495 compositions between groups of CKDB-females and HCB-females, and between CKDB-males and HCB-males. 496 The 95% confidence ellipse is drawn for each group. Permutational multivariate analysis of variance 497 (PERMANOVA) was performed for statistical comparisons of samples in the two groups. P value was adjusted by 498 the Benjamini and Hochberg false discovery rate (FDR). (B) Venn diagrams were made to compare the ASV 499 composition within different groups. Each intersection of a number of areas represents the number of ASVs, which 500 are present in all the intersecting areas. (C) Bacterial richness and diversity measured by Chao 1 and Shannon 501 index were calculated at ASV level. Wilcoxon rank-sum test was performed and adjusted by Benjamini and 502 Hochberg false discovery rate (FDR). ***, $P_{adj} < 0.001$. (D) Microbial profile at the phylum and genus level. Only 503 the top 5 most abundant phylum and the top 15 most abundant genus are shown.

504	Abrreviations: CKDB-female: urine samples provided by females with CKD; CKDB-male: urine samples
505	provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-female: urine
506	samples provided by healthy males.

507

- Figure 2 Bacterial genera that were differentially abundant between CKD patients and controls. (A) Bacterial
 genera significantly decreased in CKDB-females comparing to those in HCB-females. (B) Bacterial genera
 significantly increased in CKDB-females comparing to those in HCB-females. P value was calculated using
 Wilcoxon rank-sum test and adjusted by Benjamini and Hochberg FDR. *, FDR < 0.05; **, FDR<0.01; and ***,
 FDR< 0.001.
- Abrreviations: CKDB-female: urine samples provided by females with CKD; CKDB-male: urine samples
 provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-female: urine
 samples provided by healthy males.

516

Figure 3 Comparisons of numbers of subjects with visible bacterial isolates between groups of patient and HC.
Chi-square/Fisher's test was used, P values that are significant at 0.05. Bars represent the prevalence of isolates in
each group.

520 Abrreviations: CKDB-female: urine samples provided by females with CKD; CKDB-male: urine samples 521 provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-female: urine 522 samples provided by healthy males.

523

Figure 4 Bladder microbiome was associated with participants' demographics and kidney function estimators. (A) The heatmap depicted the association between the bacterial genera showing differed in CKDB-female and CKD-female's demographics and kidney function estimators. (B) The heatmap depicted the association between the bacterial genera showing differed in HCB-female and HC-female's demographics and kidney function estimators. Pearson correlation analysis was performed. The correlation of two variables with values of |r|>0.3 and P = < 0.05 are displayed. *, P = < 0.05; **, P = < 0.01; and ***, P = < 0.001.

530

Figure 5 Serum cytokines profiles in CKD females and their associations to urinary microbiome. (A) Serum
cytokines increased and decreased in CKD females compared to controls. *P* value was calculated using Wilcoxon

rank-sum test and adjusted by Benjamini and Hochberg false discovery rate (FDR). (B) Pearson correlation analysis was performed on the bacterial genera and cytokines that differed between the CKD females and controls. The correlation of two variables with values of |r|>0.3 and $P \square < \square 0.05$ are displayed. *, $P \square < \square 0.05$; **, $P \square < \square 0.01$; and ***, $P \square < \square 0.001$.

Abrreviations: CKDB-female: urine samples provided by females with CKD; CKDS-female: serum samples
provided by females with CKD; HCB-female: urine samples provided by healthy females; HCS-female: serum
samples provided by healthy females.

540

541 Figure 6 Comparisons of microbiomes in feces and urine in CKD males and females. (A) PCoA based on 542 Bray-Curtis distances ASV level showed different microbial compositions between groups of CKDF-females and 543 HCF-females, and between CKDF-males and HCF-males. The 95% confidence ellipse is drawn for each group. 544 Permutational multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of 545 samples in the two groups. P value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). (B) 546 Bacterial richness and diversity measured by Chao 1 and Shannon index were calculated at ASV level. Wilcoxon 547 rank-sum test was performed and adjusted by Benjamini and Hochberg false discovery rate (FDR). (C-F) PCoA 548 based on Bray-Curtis distances ASV level showed different microbial compositions between groups of 549 CKDF-male and CKDB-male; between HCF-males and HCB-males; between CKDF-female and CKDB-female; 550 between HCF-female and HCB-female. The 95% confidence ellipse is drawn for each group. Permutational 551 multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of samples in the two 552 groups. P value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). (G) Comparisons of 553 dissimilarity of Bray-Curtis between females and males' urine and feces in patients and controls group. Wilcoxon 554 rank-sum test was performed and adjusted by Benjamini and Hochberg false discovery rate (FDR). **, FDR < 555 0.01.

Abrreviations: CKDF-female: fecal samples provided by females with CKD; CKDF-male: fecal samples provided by males with CKD; CKDB-female: urine samples provided by males with CKD; CKDB-male: urine samples provided by males with CKD; HCF-female: fecal samples provided by females with CKD; HCF-male: fecal samples provided by males with CKD; HCB-female: urine samples provided by healthy females; HCB-male: urine samples provided by healthy males.

561

21

- 562 Table S1 Comparison of nutrient intake between CKD and HC cohort.
- 563 Student's t test on normalized continuous variables, and Wilcoxon rank-sum test on non-normal continuous
- 564 variables.
- 565
- 566 **Tables S2** Comparison of bacterial phylum abundance between CKDB-male and HCB-male.
- 567 Wilcoxon rank-sum test was applied.
- 568 Abrreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by
- bealthy males.
- 570
- 571 **Table S3** Comparison of bacterial phylum abundance between CKDB-female and HCB-female.
- 572 Wilcoxon rank-sum test was applied.
- 573 Abrreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples
- 574 provided by healthy females.
- 575
- 576 **Table S4** Comparison of bacterial genus abundance between CKDB-male and HCB-male.
- 577 Wilcoxon rank-sum test was applied.
- 578 Abrreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by
- 579 healthy males.
- 580
- 581 Table S5 Comparison of bacterial genus abundance between CKDB-female and HCB-female.
- 582 Wilcoxon rank-sum test was applied.
- 583 Abrreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples
- 584 provided by healthy females.
- 585
- 586 **Table S6** Bacteria identified using EQUC.
- 587 Abrreviations: CKDB-male: urine samples provided by males with CKD; CKDB-female: urine samples provided
- 588 by females with CKD; HCB-male: urine samples provided by healthy males; HCB-female: urine samples provided
- 589 by healthy females.
- 590

- 591 Table S7 Comparisons of samples with visible cultures between HCB-male and HCB-female.Pearson Chi-square
- 592 or Fisher's exact test was used
- 593 Abrreviations: CKDB-male: urine samples provided by males with CKD; HCB-male: urine samples provided by
- 594 healthy males.
- 595
- 596 Table S8 Comparisons of samples with visible cultures between HCB-male and HCB-female.Pearson Chi-square
- 597 or Fisher's exact test was used.
- 598 Abrreviations: CKDB-female: urine samples provided by females with CKD; HCB-female: urine samples
- 599 provided by healthy females.
- 600
- **Table S9** Comparison of samples with visible cultures between CKDB-male and HCB-male.
- 602 Pearson Chi-square or Fisher's exact test was used.
- 603 Abrreviations: CKDB-male: bladder urine samples provided by males with CKD; HCB-male: bladder urine
- 604 samples provided by healthy males.
- 605
- **Table S10** Comparison of samples with visible cultures between CKDB-female and HCB-female.
- 607 Pearson Chi-square or Fisher's exact test was used.
- Abrreviations: CKDB-female: bladder urine samples provided by females with CKD; HCB-female: bladder urine
- 609 samples provided by healthy females.
- 610
- 611 Figure S1 Stud design.
- 612 Participants enrollment and study procedures.
- 613 Abrreviations: CKDB: urine samples provided by patients with CKD; HCB: urine samples provided by healthy
- 614 controls; CKDF: fecal samples provided by patients with CKD; HCF: fecal samples provided by healthy controls;
- 615 CKDS: serum samples provided by CKD patient; HCS: serum samples provided by healthy controls.
- 616
- 617 Figure S2 Medication usages on urinary microbiome.
- 618 (A) Comparison of urinary microbiome between antihypertensive agent users and non-users; (B) Comparison of
- 619 urinary microbiome between glucocorticoid agent users and non-users; (C) Comparison of urinary microbiome

620	between hypoglycemic agent users and non-users; (D) Comparison of urinary microbiome between hypolipidemic
621	agent users and non-users. Permutational multivariate analysis of variance (PERMANOVA) was performed for
622	statistical comparisons of samples in the two groups. P value was adjusted by the Benjamini and Hochberg false

- 623 discovery rate (FDR).
- 624
- 625 Figure S3 Urinary microbiome in various CKD stages.
- 626 (A) Comparisons of microbial community between patients in CKD stage1-stage5 and controls. Permutational
- 627 multivariate analysis of variance (PERMANOVA) was performed for statistical comparisons of samples in the two
- 628 groups. P value was adjusted by the Benjamini and Hochberg false discovery rate (FDR). (B) Comparisons of
- 629 microbial richness and diversity between patients in CKD stage1-stage5 and controls. Wilcoxon rank-sum test was
- 630 performed and adjusted by Benjamini and Hochberg false discovery rate (FDR).
- 631

632 **References**

633	1.	Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and
634		national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global
635		Burden of Disease Study 2017. The Lancet. 2020;395(10225):709-33.
636	2.	Meijers B, Evenepoel P, Anders HJ. Intestinal microbiome and fitness in kidney disease. Nat Rev
637		Nephrol. 2019;15(9):531-45.
638	3.	Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, et al. Blood Microbiome
639		Profile in CKD : A Pilot Study. Clin J Am Soc Nephrol. 2019;14(5):692-701.
640	4.	Hilt EE, Mckinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, et al. Urine is not
641		sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult
642		female bladder. J Clin Microbiol. 2014;52(3):871-6.
643	5.	Wolfe AJ, Toh E, Shibata N, Rong R, Kenton K, Fitzgerald M, et al. Evidence of uncultivated
644		bacteria in the adult female bladder. J Clin Microbiol. 2012;50(4):1376-83.
645	6.	Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, et al. The female
646		urinary microbiome: a comparison of women with and without urgency urinary incontinence.
647		Mbio. 2014;5(4):e1214-83.
648	7.	Liu F, Du J, Zhai Q, Hu J, Miller AW, Ren T, et al. The Bladder Microbiome, Metabolome,
649		Cytokines, and Phenotypes in Patients with Systemic Lupus Erythematosus. Microbiol Spectr.
650		2022:e21222.
651	8.	Roth RS, Liden M, Huttner A. The urobiome in men and women: a clinical review. Clin
652		Microbiol Infect. 2022.
653	9.	Kachroo N, Lange D, Penniston KL, Stern J, Tasian G, Bajic P, et al. Meta-analysis of Clinical
654		Microbiome Studies in Urolithiasis Reveal Age, Stone Composition, and Study Location as the
655		Predominant Factors in Urolithiasis-Associated Microbiome Composition. Mbio.

656		2021;12(4):e200721.
657	10.	Vaughan MH, Mao J, Karstens LA, Ma L, Amundsen CL, Schmader KE, et al. The Urinary
658		Microbiome in Postmenopausal Women with Recurrent Urinary Tract Infections. J Urol.
659		2021;206(5):1222-31.
660	11.	Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, et al. Profiling the Urinary Microbiota in
661		Male Patients With Bladder Cancer in China. Front Cell Infect Microbiol. 2018;8:167.
662	12.	Kramer H, Kuffel G, Thomas-White K, Wolfe AJ, Vellanki K, Leehey DJ, et al. Diversity of the
663		midstream urine microbiome in adults with chronic kidney disease. Int Urol Nephrol.
664		2018;50(6):1123-30.
665	13.	Frimodt-Møller N. The urine microbiome – Contamination or a novel paradigm?
666		Ebiomedicine. 2019;44:20-1.
667	14.	Brubaker L, Gourdine JF, Siddiqui NY, Holland A, Halverson T, Limeria R, et al. Forming
668		Consensus To Advance Urobiome Research. Msystems. 2021;6(4):e137120.
669	15.	Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine dysregulation in chronic kidney
670		disease: how can we treat it? Blood Purif. 2008;26(3):291-9.
671	16.	Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, et al. Inflammation and
672		Progression of CKD: The CRIC Study. Clin J Am Soc Nephrol. 2016;11(9):1546-56.
673	17.	Salguero MV, Al Obaide MAI, Singh R, Siepmann T, Vasylyeva TL. Dysbiosis of
674		Gram negative gut microbiota and the associated serum lipopolysaccharide exacerbates
675		inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med.
676		2019;18(5):3461-9.
677	18.	Linh HT, Iwata Y, Senda Y, Sakai-Takemori Y, Nakade Y, Oshima M, et al. Intestinal Bacterial
678		Translocation Contributes to Diabetic Kidney Disease. J Am Soc Nephrol. 2022;33(6):1105-19.
679	19.	Tao S, Li L, Li L, Liu Y, Ren Q, Shi M, et al. Understanding the gut-kidney axis among
680		biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis
681		of the gut microbiota composition. Acta Diabetol. 2019;56(5):581-92.
682	20.	Liu F, Du J, Zhai Q, Hu J, Miller AW, Ren T, et al. The Bladder Microbiome, Metabolome,
683		Cytokines, and Phenotypes in Patients with Systemic Lupus Erythematosus. Microbiol Spectr.
684		2022:e21222.
685	21.	Liu F, Zhang N, Jiang P, Zhai Q, Li C, Yu D, et al. Characteristics of the urinary microbiome in
686		kidney stone patients with hypertension. J Transl Med. 2020;18(1):130.
687	22.	Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Fernandez-Fernandez
688		B, Martin-Cleary C, et al. Clarifying the concept of chronic kidney disease for non-nephrologists.
689		Clin Kidney J. 2019;12(2):258-61.
690	23.	Fengping L, Jingjie D, Qixiao Z, Jialin H, Aaron W M, Tianli R, et al. The bladder microbiome,
691		metabolome, cytokines, and phenotypes in patients with systemic lupus erythematosus.
692		Mycobiology Spectrum. 2022.
693	24.	Hilt EE, Mckinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, et al. Urine is not
694		sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult
695		female bladder. J Clin Microbiol. 2014;52(3):871-6.
696	25.	Guo X, Kim J, Nam H, Park S, Kim J. Screening lactic acid bacteria from swine origins for
697		multistrain probiotics based on in vitro functional properties. Anaerobe. 2010;16(4):321-6.
698	26.	Mesureur J, Arend S, Celliere B, Courault P, Cotte-Pattat PJ, Totty H, et al. A MALDI-TOF MS
699		database with broad genus coverage for species-level identification of Brucella. PLoS Negl Trop

700		Dis. 2018;12(10):e6874.
701	27.	Pohl HG, Groah SL, Perez-Losada M, Ljungberg I, Sprague BM, Chandal N, et al. The Urine
702		Microbiome of Healthy Men and Women Differs by Urine Collection Method. Int Neurourol J.
703		2020;24(1):41-51.
704	28.	Gottschick C, Deng ZL, Vital M, Masur C, Abels C, Pieper DH, et al. The urinary microbiota of
705		men and women and its changes in women during bacterial vaginosis and antibiotic treatment.
706		Microbiome. 2017;5(1):99.
707	29.	Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology,
708		mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-84.
709	30.	Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frolich R, et al. Safety,
710		immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic
711		Escherichia coli in women with a history of recurrent urinary tract infection: a randomised,
712		single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017;17(5):528-37.
713	31.	Song CH, Kim YH, Naskar M, Haves BW, Abraham MA, Noh JH, et al. Lactobacillus crispatus
714		Limits Bladder Uropathogenic E. coli Infection by Triggering a Host Type I Interferon
715		Response. Proc Natl Acad Sci U S A. 2022;119(33):e2117904119.
716	32.	Price TK, Dune T, Hilt EE, Thomas-White KJ, Kliethermes S, Brincat C, et al. The Clinical Urine
717		Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms. J Clin
718		Microbiol. 2016;54(5):1216-22.
719	33.	Wu IW, Gao SS, Chou HC, Yang HY, Chang LC, Kuo YL, et al. Integrative metagenomic and
720		metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney
721		disease. Theranostics. 2020;10(12):5398-411.
722	34.	Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology
723		and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14(3):151-64.
724	35.	Pearce MM, Zilliox MJ, Rosenfeld AB, Thomas-White KJ, Richter HE, Nager CW, et al. The
725		female urinary microbiome in urgency urinary incontinence. Am J Obstet Gynecol.
726		2015;213(3):341-7.
727	36.	Abernethy MG, Rosenfeld A, White JR, Mueller MG, Lewicky-Gaupp C, Kenton K. Urinary
728		Microbiome and Cytokine Levels in Women With Interstitial Cystitis. Obstet Gynecol.
729		2017;129(3):500-6.
730	37.	Kim H, Nam BY, Park J, Song S, Kim WK, Lee K, et al. Lactobacillus acidophilus KBL409
731		Reduces Kidney Fibrosis via Immune Modulatory Effects in Mice with Chronic Kidney Disease.
732		Mol Nutr Food Res. 2022:e2101105.
733	38.	Tungsanga S, Katavetin P, Panpetch W, Udompornpitak K, Saisorn W, Praditpornsilpa K, et al.
734		Lactobacillus rhamnosus L34 attenuates chronic kidney disease progression in a 5/6
735		nephrectomy mouse model through the excretion of anti-inflammatory molecules. Nephrol Dial
736		Transplant. 2022;37(8):1429-42.
737	39.	Komesu YM, Dinwiddie DL, Richter HE, Lukacz ES, Sung VW, Siddiqui NY, et al. Defining the
738		relationship between vaginal and urinary microbiomes. Am J Obstet Gynecol. 2020;222(2):151-4.
739	40.	Curtiss N, Balachandran A, Krska L, Peppiatt-Wildman C, Wildman S, Duckett J. Age,
740		menopausal status and the bladder microbiome. Eur J Obstet Gynecol Reprod Biol.
741		2018;228:126-9.
742	41.	Ellam T, Twohig H, Khwaja A. Chronic kidney disease in elderly people: disease or disease label?
743		BMJ. 2016;352:h6559.

744	42.	Ming J, Yu X, Xu X, Wang L, Ding C, Wang Z, et al. Effectiveness and safety of Bifidobacterium
745		and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a
746		multi-center, double-blind, randomized, parallel-controlled study. Genome Med.
747		2021;13(1):125.
748	43.	Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein MC, et al. Chemokine monokine
749		induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and
750		effector cytokine production. J Immunol. 2004;172(12):7417-24.
751	44.	Lee MH, Laajala E, Kreutzman A, Jarvinen P, Nisen H, Mirtti T, et al. The tumor and plasma
752		cytokine profiles of renal cell carcinoma patients. Sci Rep. 2022;12(1):13416.
753	45.	Suen JL, Liu CC, Lin YS, Tsai YF, Juo SH, Chou YH. Urinary chemokines/cytokines are
754		elevated in patients with urolithiasis. Urol Res. 2010;38(2):81-7.
755	46.	Mahlen SD, Clarridge JR. Site and clinical significance of Alloscardovia omnicolens and
756		Bifidobacterium species isolated in the clinical laboratory. J Clin Microbiol.
757		2009;47(10):3289-93.
758	47.	Pathak P, Trilligan C, Rapose A. Bifidobacteriumfriend or foe? A case of urinary tract infection
759		with Bifidobacterium species. BMJ Case Rep. 2014;2014.
760	48.	Bhaskar MM, Sistla S, Kumaravel S. A case of pyometrocolpos with Bifidobacterium species.
761		Anaerobe. 2017;44:48-50.
762	49.	Komada T, Muruve DA. The role of inflammasomes in kidney disease. Nat Rev Nephrol.
763		2019;15(8):501-20.
764	50.	Vianna HR, Soares CM, Silveira KD, Elmiro GS, Mendes PM, de Sousa TM, et al. Cytokines in
765		chronic kidney disease: potential link of MCP-1 and dyslipidemia in glomerular diseases.
766		Pediatr Nephrol. 2013;28(3):463-9.
767	51.	Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between
768		albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am
769		Soc Nephrol. 2012;7(12):1938-46.
770	52.	Shoskes D, Altemus J, Polackwich A, Tucky B, Wang H, Eng C. The Urinary Microbiome
771		Differs Significantly Between Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
772		and Controls as Well as Between Patients With Different Clinical Phenotypes. Urology.
773		2016;92:26-32.
774	53.	Zhu Z, Satten GA, Mitchell C, Hu YJ. Constraining PERMANOVA and LDM to within-set
775		comparisons by projection improves the efficiency of analyses of matched sets of microbiome
776		data. Microbiome. 2021;9(1):133.
777	54.	Mcwilliams R, Hoover-Fong J, Hamosh A, Beck S, Beaty T, Cutting G. Problematic variation in
778		local institutional review of a multicenter genetic epidemiology study. JAMA.
779		2003;290(3):360-6.
780		

























Abbreviations

CKDB: CKD patient's bladder; HCB: healthy control's bladder; CKDF: CKD patient's feces; HCF: healthy control's feces; CKDS: CKD patient's serum; HCS: healthy control's serum





CKOBSING®

HCS



CHUB-STAR^{® 3}

HCB

CKOP5588 * HCB

CHUB-SIAGES

HCB

